Investigation of Efficacy of Secukinumab in Patients With Moderate to Serve Atopic Dermatitis

NCT ID: NCT03568136

Last Updated: 2021-05-03

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 22 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-09-18
• Study Completion Date: 2020-05-04

Brief Summary

The overall aim of this study is to assess the effects of a new treatment called Secukinumab in adults suffering from moderate to severe atopic dermatitis. Furthermore, the study shall support the extension of the approval for Secukinumab from psoriasis to atopic dermatitis. The effectiveness of Secukinumab is determined on the reduction of the eczema score EASI 50 (Eczema Area and Severity Index, a tool to measure the severity of atopic dermatitis) at week 4.

Detailed Description

Secukinumab is a humanized anti-IL-17A monoclonal antibody. Since Secukinumab is well established in the therapy of psoriasis with a highly favorable benefit to risk ration and IL-17 has been described in atopic dermatitis this study aims to investigate the effects of anti-IL-17 in atopic dermatitis.

This is a randomized, placebo-controlled, multicenter, double-blinded study to evaluate the efficacy and safety of subcutaneous Secukinumab compared to placebo in 45 adults with atopic dermatitis.

The study consists of 3 periods: a screening period of at least -14 days and up to -35 days, and a treatment period of 16 weeks and a follow-up period of additional 8 weeks. During the screening period eligibility of the patients is confirmed. Eligible patients are randomized 2:1 to treatment arm A or B at Day -7 (+2 to -15) during the randomization visit. Secukinumab (Cosentyx®) will be used according to the official label and SmPC (Summary of Product Characteristics). Patients in treatment arm A receive 300 mg Secukinumab administered as 2 subcutaneous injections of 150 mg (i.e. 2x 150 mg) at baseline day 1 and week 1, 2, 3, 4, 8, 12 and injections with placebo at week 5, 6, 7 and 16. For assessments of the study endpoints visits are performed at weeks 20 and 24. Placebo will be administered as 2 subcutaneous injections. Patients in treatment arm B receive placebo until visit 3 (week 3) and will switch to Secukinumab 300 mg s.c. up from visit 4 (week 4), visit 5, 6, 7, 8, 12 and16. For assessments of the study endpoints visits are performed at weeks 20 and 24.

Conditions

Dermatitis, Atopic; Eczema, Atopic; Neurodermatitis, Atopic

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Treatment Arm A

Patients in treatment arm A receive 300 mg Secukinumab administered as 2 subcutaneous injections of 150 mg (i.e. 2x 150 mg) at baseline day 1 and week 1, 2, 3, 4, 8, 12 and injections with placebo at week 5, 6, 7 and 16. For assessments of the study endpoints were followed up visits at week 20 and 24. Placebo will be administered as 2 subcutaneous injections.

Group Type: EXPERIMENTAL

Secukinumab 300 mg

Intervention Type: DRUG

Solution for injection in pre-filled syringe

Placebo

Intervention Type: DRUG

Solution for injection in pre-filled syringe

Treatment Arm B

Patients in treatment arm B receive placebo until visit 3 (week 3) and will switch to Secukinumab 300 mg s.c. up from visit 4 (week 4), visit 5, 6, 7, 8, 12 and16. For assessments of the study endpoints were followed up visits at week 20 and 24.

Group Type: PLACEBO_COMPARATOR

Secukinumab 300 mg

Intervention Type: DRUG

Solution for injection in pre-filled syringe

Placebo

Intervention Type: DRUG

Solution for injection in pre-filled syringe

Interventions

Secukinumab 300 mg

Solution for injection in pre-filled syringe

Intervention Type: DRUG

Placebo

Solution for injection in pre-filled syringe

Intervention Type: DRUG

Other Intervention Names

COSENTYX ®; Placebo (for Secukinumab)

Eligibility Criteria

Inclusion Criteria

1. Atopic dermatitis (intrinsic disease without IgE mediated sensitization defined by negative history and negative SX-1 CAP FEIA or extrinsic disease defined by positive history and / or positive SX-1 CAP FEIA),

2. SCORAD index score ≥ 25,

3. EASI ≥ 16,

4. Male and female patients at the age of 18 to 85 years,

5. Signed Informed Consent,

6. Subjects must be able to understand and communicate with the investigator and comply with the requirements of the study and must give a written, signed and dated informed consent before any study related activity is performed,

7. Subject is judged to be in good general health as determined by the principal investigator based upon the results of medical history, laboratory profile, and physical examination,

8. Patients with stable chronic asthma, treated with inhaled corticosteroids, will be allowed to participate.

Exclusion Criteria

1. Other inflammatory skin disease than atopic dermatitis,

2. Use of cyclosporine, azathioprine, mycophenolate [wash-out period of 4 weeks]; Phototherapy (PUVA, NB-UVB, UVA1; [wash-out period of 2 weeks]), Dupilumab (Dupixent®; [wash-out period of 12 weeks])

3. Subjects expected to be exposed to an undue safety risk if participating in the trial including chronic infections,

4. Contraindications of Secukinumab by label (i.e. approval for the treatment of psoriasis in the EU - refer to point 14 - 16 at the bottom of this section),

5. Current severe progressive or uncontrolled disease which in the judgment of the investigator renders the subject unsuitable for the trial,

6. Plans for administration of live vaccines during the study period,

7. Chronic infection,

8. Patients with instable chronic asthma,

9. Any chronic inflammatory bowel disease (e.g. Crohn's disease),

10. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (>10 mIU/mL),

11. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unwilling to use effective contraception during the study and for 20 weeks after stopping treatment. Effective contraception is defined as either:

1. Barrier method: Condom or occlusive cap (diaphragm or cervical/vault caps) with spermicide (where available). Spermicides alone are not a barrier method of contraception and should not be used alone,

The following methods are considered more effective than the barrier method and are also acceptable:

2. Total abstinence: When this is in line with the preferred and usual lifestyle of the subject (Periodic abstinence [e.g. calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception),

3. Female sterilization: have had a surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment,

4. Male partner sterilization (at least 6 months prior to screening). For female subjects on the study, the vasectomized male partner should be the sole partner for that subject,

5. Use of established oral, injected or implanted hormonal methods of contraception, intrauterine device (IUD) or intrauterine system (IUS) NOTE: Women are considered post-menopausal and not of child bearing potential if they have had:

i. 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or • six months of spontaneous amenorrhea with serum FSH levels >40 mIU/mL

Or

ii. Surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.

12. History of human immunodeficiency virus (HIV) infection or positive HIV serology at screening,

13. Positive with hepatitis B surface antigen (HBsAg) or hepatitis C antibody at the screening visit (a report ≤ 6 months is also accepted),

14. History of alcohol or drug abuse within 1 year of the screening visit,

15. Planned major surgical procedure during the patient's participation in this study,

16. Hypersensitivity against Secukinumab,

17. Active or reactive tuberculosis,

18. Participation in other clinical studies.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Novartis Pharmaceuticals

INDUSTRY

Sponsor Role: collaborator

GWT-TUD GmbH

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Stefan Beissert, Prof. Dr.

Role: PRINCIPAL_INVESTIGATOR

Locations

Klinische Forschung Dresden GmbH

Dresden, , Germany

Carl Gustav Carus University Hospital, Department of Dermatology

Dresden, , Germany

SRH Wald-Klinikum Gera, Center for Clinical Studies

Gera, , Germany

Hannover Medical School, Department for Dermatology, Allergy and Venereology

Hanover, , Germany

SIBAmed Studienzentrum GmbH & Co KG

Leipzig, , Germany

Countries

Germany

Other Identifiers

2016-005181-57

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

Secu_Trial

Identifier Type: -

Identifier Source: org_study_id